News about 'Uncategorized'

TB Alliance announced that its compound TBA-354 has started Phase I clinical trials. This announcement is particularly exciting given that TBA-354 is the first TB drug to enter Phase I trials since 2009. TBA-354 is a next generation compound in the nitroimidazole class, which also includes...

Researchers at the Center for Tuberculosis Research located at Johns Hopkins University School of Medicine have shown that heart medication, verapamil administered in combination with bedaquline lowers the toxicity of the TB drug without altering its efficacy. The paper, titled ‘ Verapamil...

22 OCTOBER 2014 AT 12:01 a.m. EDT CONTACT Mike Frick, Treatment Action Group +1 405.388.4490 New York, NEW YORK, OCTOBER 22, 2014 —Worldwide, governments, foundations, and companies invested US$676.7 million in research to develop new drugs, vaccines, and diagnostics against tuberculosis (TB) in...

We invite you to join us for the Stop TB Partnership Working Group on New Drugs’ Annual Meeting 2014 at AC Hotel Barcelona Forum , Barcelona, Spain, on Wednesday, Oct. 29th from 15:00 to 19:00. This meeting is held before the 45th Union World Conference on Lung Health (The Union). During the...

Moxifloxacin Results of the Phase III REMoxTB clinical trial were published in the New England Journal of Medicine on September 7th, 2014. REMox or Rapid Evaluation of Moxifloxacin in Tuberculosis (REMoxTB) was a trial designed to determine whether replacement of either ethambutol or isoniazid with...

Scientists at Janssen Pharmaceutica have characterized a novel resistance mechanism to Bedaquiline (BDQ), a second line antibiotic for the treatment of MDR-TB. The research study , published in Plos One , showed that tuberculosis resisted BDQ treatment by developing a mechanism to pump the drug out...

A new study published by Dr. Kyu Rhee ’s laboratory at the Weill Cornell Medical College details a potential mechanism driving Mycobacterium tuberculosis’ intrinsic resistance to antibiotics. Physicians and scientists have known for many years that tuberculosis is intrinsically resistant to...

On June 9 th , the Center for Strategic and International Studies (CSIS) released six policy reports detailing the domestic and global health burden of tuberculosis and recommendations for the United States government to combat the disease. The policy reports were the culmination of major findings...

The Kick TB Campaign is a unique project that uses football (soccer), the World’s most popular sport, to educate and engage young people in the effort to stop the spread of tuberculosis. First inaugurated in South Africa during the 2010 World Cup, Kick TB has expanded to Brazil, the host country of...

Dr. Iwao Ojima Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. His group recently published a paper in PLOS One entitled A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against...

The European Commission has approved Delaminid (Deltyba™) for use in patients suffering from MDR-TB. Delamanid was developed by Otsuka Pharmaceutical Co., Ltd., a Japanese pharmaceutical company dedicated to drug discovery for tuberculosis. The press release from Otsuka can be found here Related...

TB Alliance , an international non-profit whose mission is to develop better and more affordable drugs against tuberculosis, made three announcements on World TB Day demonstrating their commitment to combating childhood TB. Web portal for childhood TB On World TB Day, the TB Alliance in partnership...

Update: Release of Part 1 of EXPOSED scheduled for the week of May 20. Contact jrosen@aeras.org if you would like to host a screening event or get more information. EXPOSED is a four-part series of short films that tell the story of the deadly global epidemic of tuberculosis. The series will...

This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University’s Shanghai Public Health Clinical Center in China. He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.

Click here to read full report. The 2012 Millennium Development Report was just released highlighting progress made to date. Great strides have been made in HIV and TB from the year 1990 (see below). The Global Plan to Stop TB issued by the Stop TB Partnership is set within the context of the...